基是掩盖的氧化物,可共性抑制GPX4
John K Eaton1, Richard A Ruberto1, Anneke Kramm1
1Broad Institute of MIT and Harvard , Cambridge , Massachusetts 02142 , United States.
Journal of the American Chemical Society
|December 17, 2019
概括
迪亚西尔富洛桑可以共同抑制谷氨过氧化酶4 (GPX4). 这一发现为向抗药性癌症的关键蛋白质GPX4提供了一种新的机制,扩大了治疗选择.
科学领域:
- 医学化学
- 生物化学
- 癌症学
背景情况:
- 氨酸过氧化酶4 (GPX4) 是一个具有挑战性的治疗点,特别是在耐药癌症中.
- 目前的GPX4抑制剂主要使用乙分片来对催化类固醇残留物进行共价修饰.
- 多种GPX4抑制剂发现了针对该酶的新型电友核弹头.
研究的目的:
- 发现和描述新的共价GPX4抑制剂.
- 阐明作为GPX4抑制剂的二甲基的分子作用机制.
- 探索针对GPX4的新反应组.
主要方法:
- 迪亚基的合成和表征.
- 评估GPX4抑制的生物化学测试.
- 细胞测试以评估独特的反应性和有效性.
主要成果:
- 迪亚基素作为掩盖的氧化物前药物.
- 这些化合物具有明显的细胞和生化反应性,并共同抑制GPX4.
- 该机制与现有的GPX4抑制剂不同.
结论:
- 迪亚西尔富洛桑是一种新型GPX4抑制剂.
- 这项研究揭示了furoxan生物活性的新分子机制.
- 这些发现扩大了针对GPX4的化学策略.
相关概念视频
GPCRs Regulate Adenylyl Cylase Activity
7.1K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.1K
GPCR Desensitization
7.8K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
7.8K
Eukaryotic Transcription Inhibitors
10.8K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.8K
Dipeptidyl Peptidase 4 Inhibitors
519
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
519
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
856
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
856
Transducer Mechanism: G Protein–Coupled Receptors
3.7K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
3.7K


